Syneos Health Osake

Syneos Health PEG

Delisted·29.9.2023

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Syneos Health (SYNH) 12.8.2026 päivämäärällä on 0,63. Edellisenä vuonna PEG-suhde (Hinta-tuotto-kasvu-suhde) oli 0,71 — muutos −11,88 % (matalampi).

PEG

0,63

YoY

−11,88%

Viimeksi päivitetty:

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Syneos Health on 2026 0,63 . PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Syneos Health oli 2025 0,71 . Se laskee −11,88% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Syneos Health Osakeanalyysi

Mitä Syneos Health tekee? Syneos Health is a US-based pharmaceutical and biotech service company. They specialize in providing integrated solutions for clinical research, commercial services, and data analysis. The company was founded in 2017 through the merger of two leading service companies, INC Research and inVentiv Health. Today, Syneos Health is one of the largest providers of clinical and commercial services in the pharmaceutical and biotech industry. They support their customers in the development and marketing of medications, diagnostics, and medical devices by offering a wide range of services including planning and conducting clinical trials, data analysis and management, and product marketing. Syneos Health operates in four business areas: clinical solutions, commercial solutions, consulting services, and clinical data analysis. Their primary focus is on delivering customer-centric services that cover various aspects of the pharmaceutical and biotech industry value chain. Within their clinical and medical segment, they conduct clinical trials and provide supporting services. They have expertise in clinical research and have successfully executed numerous studies. Syneos Health also offers consulting services in the areas of data management systems and clinical trials. In the commercial segment, they assist customers with marketing, sales promotion, and channel management to ensure the successful launch and sales of products. They provide training for sales staff, market research and analysis, and continuous support from sales and marketing experts. Their consulting services encompass strategy consulting, market research, branding, and communication. They also assist with the development, implementation, and validation of clinical trials, literature research, and regulatory support. Syneos Health's clinical data analysis involves analyzing large data sets to gain insights into the healthcare industry. They utilize cutting-edge technologies such as Big Data Analytics and Machine Learning to provide customers with valuable insights that aid in decision-making. In addition to clinical trials and consulting, Syneos Health offers modern technologies for the development and marketing of medications. This includes Virtual Reality solutions, personalized patient programs for chronic disease treatment, and digital platforms for data collection, analysis, and management. Syneos Health serves globally operating pharmaceutical and biotech companies that rely on their services to develop and market innovative medications and treatment methods. Customers value Syneos Health's expertise and trust that the company will help them successfully bring their products to market. Overall, Syneos Health is a leading company in the pharmaceutical and biotech industry. Their integrated services enable customers to work faster and more effectively. By combining expertise in clinical research, commercial solutions, consulting services, and clinical data analysis, Syneos Health offers innovative and successful solutions to its customers. Syneos Health on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Syneos Health osakkeesta

Yhtiön Syneos Health PEG-suhde (Hinta-tuotto-kasvu-suhde) on 0,63 vuonna 2026.

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Syneos Health muuttui arvosta 0,71 arvoon 0,63, mikä edustaa −11,88 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää PEG-suhde (Hinta-tuotto-kasvu-suhde) Syneos Health:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

PEG-suhde korjaa P/E-suhteen odotetulla tuottojen kasvuvauhdilla. PEG alle 1 voi viitata osakkeeseen, joka on aliarvostettu suhteessa sen kasvupotentiaaliin.

PEG = P/E-suhde / Odotettu vuosittainen EPS-kasvuprosentti

Arvioidakseen PEG-suhde (Hinta-tuotto-kasvu-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja PEG-suhde (Hinta-tuotto-kasvu-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata PEG-suhde (Hinta-tuotto-kasvu-suhde):n Syneos Health alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Syneos Health

Kaikki tunnusluvut — Syneos Health